মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

wilshire pharmaceuticals - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride extended-release capsules are indicated to prolong the time to recurrence of symptomatic atrial fibrillation (af) in patients with episodic (most likely paroxysmal or persistent) af who do not have structural heart disease. usage considerations: - the use of propafenone hydrochloride extended-release capsules in patients with permanent af or in patients exclusively with atrial flutter or paroxysmal supraventricular tachycardia (psvt) has not been evaluated. do not use propafenone hydrochloride extended-release capsules to control ventricular rate during af. - some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. concomitant treatment with drugs that increase the functional atrioventricular (av) nodal refractory period is recommended. - the effect of propafenone on mortality has not been determined [see boxed warning] . propafenone hydrochloride extended-release capsules are contraindicated in the following

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

wilshire pharmaceuticals, inc. - sevelamer carbonate (unii: 9ycx42i8iu) (sevelamer - unii:941n5duu5c) - sevelamer carbonate tablets are indicated for the control of serum phosphorus in adults with chronic kidney disease (ckd) on dialysis. pediatric use information is approved for genzyme corporation's renvela (sevelamer carbonate) tablets and renvela (sevelamer carbonate) for oral suspension. however, due to genzyme corporation's marketing exclusivity rights, these drug products are not labeled with that pediatric information. sevelamer carbonate tablets are contraindicated in patients with bowel obstruction. sevelamer carbonate tablets are contraindicated in patients with known hypersensitivity to sevelamer carbonate, sevelamer hydrochloride, or to any of the excipients. risk summary sevelamer carbonate is not absorbed systemically following oral administration and maternal use is not expected to result in fetal exposure to the drug. clinical considerations sevelamer carbonate may decrease serum levels of fat soluble vitamins and folic acid in pregnant women [see clinical pharmacology (12.2)] . consider supple

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

wilshire pharmaceuticals - hydralazine hydrochloride (unii: fd171b778y) (hydralazine - unii:26nak24ls8), isosorbide dinitrate (unii: ia7306519n) (isosorbide dinitrate - unii:ia7306519n) - isosorbide dinitrate and hydralazine hydrochloride tablets are indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient-reported functional status. there is little experience in patients with nyha class iv heart failure. isosorbide dinitrate and hydralazine hydrochloride tablets are contraindicated in patients who are allergic to organic nitrates. do not use isosorbide dinitrate and hydralazine hydrochloride tablets in patients who are taking pde-5 inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1)] . do not use isosorbide dinitrate and hydralazine hydrochloride tablets in patients who are taking the soluble guanylate cyclase (sgc) stimulator riociguat. concomitant use can cause hypotension. risk summary there are no data on isosorbide

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

wilshire pharmaceuticals, inc. - vancomycin hydrochloride (unii: 71wo621tjd) (vancomycin - unii:6q205eh1vu) - vancomycin hydrochloride is indicated for the treatment of clostridium difficil e‑associated diarrhea in adults and pediatric patients less than 18 years of age. vancomycin hydrochloride is also indicated for the treatment of enterocolitis caused by staphylococcus aureus (including methicillin‑resistant strains) in adults and pediatric patients less than 18 years of age. important limitations of use to reduce the development of drug‑resistant bacteria and maintain the effectiveness of vancomycin hydrochloride and other antibacterial drugs, vancomycin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. vancomycin hydrochloride is contraindicated in patients with kn

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

wilshire pharmaceuticals, inc. - baclofen (unii: h789n3fke8) (baclofen - unii:h789n3fke8) - baclofen is indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. baclofen may also be of some value in patients with spinal cord injuries and other spinal cord diseases. limitations of use baclofen is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. baclofen oral suspension is contraindicated in patients with hypersensitivity to baclofen. there are no adequate data on the risk of major birth defects, miscarriages, or other maternal adverse outcomes associated with the use of baclofen in pregnant women. there are adverse effects on fetal outcomes associated with withdrawal from baclofen after delivery (see clinical considerations) . oral administration of baclofen to pregnant rats resulted in an increased incidence of fetal structural abnormalities at a dose that was also associated with maternal toxicity. the background risk of major birth defects

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

wilshire pharmaceuticals - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate and other antibacterial drugs, erythromycin ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin ethylsuccinate is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes , streptococcus pneumoniae , or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrati

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

wilshire pharmaceuticals - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin delayed-release tablets and other antibacterial drugs, erythromycin delayed-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin delayed-release tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible t

ভারত - ইংরেজি - Central Drugs Standard Control Organization

wilshire - lycopene,vit.a,vit.c,vit.e,zinc sulph.,selenium - cap - 2000mg,2500iu.,50mg,10mg,45mg,70mg - 10

ভারত - ইংরেজি - Central Drugs Standard Control Organization

wilshire - calcium citrate,vit.d3 - tab - 10*10

ভারত - ইংরেজি - Central Drugs Standard Control Organization

wilshire - cyproheptadine hcl.,sorbitol sol.,tricholine citrate - syr - 2,3.575,275;mg - syr